Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer

Michael Burke, Sawsan Rashdan

Research output: Contribution to journalReview articlepeer-review

Abstract

With proven efficacy of the use of immunotherapy in almost all stages of NSCLC, immunotherapy toxicity has become a very important topic that requires immediate recognition and management. The diagnosis of toxicities associated with immunotherapy in lung cancer can be very challenging and often requires multidisciplinary effort. This mini review gives an overview of the diagnosis and management of immune-related adverse events that arise from using immunotherapy in NSCLC, as well as the potential biomarkers for its early identification and future directions.

Original languageEnglish (US)
Article number720759
JournalFrontiers in Oncology
Volume11
DOIs
StatePublished - Sep 30 2021
Externally publishedYes

Keywords

  • adverse events
  • checkpoint inhibitor
  • immunotherapy
  • lung cancer
  • steroids
  • toxicity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer'. Together they form a unique fingerprint.

Cite this